Quadrature Capital Ltd Invests $1.27 Million in Encompass Health Co. (NYSE:EHC)

Quadrature Capital Ltd purchased a new stake in Encompass Health Co. (NYSE:EHC) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 15,428 shares of the company’s stock, valued at approximately $1,274,000.

Several other institutional investors also recently bought and sold shares of the company. TD Asset Management Inc grew its holdings in shares of Encompass Health by 239.6% during the fourth quarter. TD Asset Management Inc now owns 1,969,186 shares of the company’s stock worth $131,384,000 after buying an additional 1,389,275 shares in the last quarter. 8 Knots Management LLC purchased a new position in Encompass Health in the 4th quarter worth approximately $75,424,000. Norges Bank acquired a new position in shares of Encompass Health during the 4th quarter worth approximately $69,178,000. Epoch Investment Partners Inc. grew its position in shares of Encompass Health by 102.9% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,399,341 shares of the company’s stock valued at $93,364,000 after purchasing an additional 709,593 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Encompass Health by 379.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 578,349 shares of the company’s stock valued at $38,587,000 after purchasing an additional 457,796 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Encompass Health

In related news, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP John Patrick Darby sold 14,543 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $83.94, for a total value of $1,220,739.42. Following the sale, the executive vice president now owns 84,773 shares in the company, valued at approximately $7,115,845.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Mark J. Tarr sold 44,976 shares of Encompass Health stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total value of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The disclosure for this sale can be found here. Insiders sold a total of 69,519 shares of company stock valued at $5,816,091 in the last three months. 2.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on EHC shares. Stephens reissued an “overweight” rating and issued a $94.00 price objective on shares of Encompass Health in a report on Wednesday, June 5th. Royal Bank of Canada raised their price target on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, May 22nd. Leerink Partnrs upgraded Encompass Health to a “strong-buy” rating in a report on Wednesday, July 10th. Truist Financial increased their price objective on Encompass Health from $95.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Mizuho lifted their target price on Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $96.50.

Encompass Health Stock Up 1.1 %

Shares of EHC traded up $0.97 during midday trading on Friday, hitting $91.61. The company had a trading volume of 573,003 shares, compared to its average volume of 590,017. Encompass Health Co. has a 1 year low of $57.55 and a 1 year high of $91.96. The firm has a market capitalization of $9.22 billion, a P/E ratio of 24.76, a P/E/G ratio of 1.42 and a beta of 0.89. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. The company’s 50-day simple moving average is $85.59 and its 200-day simple moving average is $80.22.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the previous year, the company earned $0.88 EPS. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. As a group, sell-side analysts expect that Encompass Health Co. will post 4.09 EPS for the current year.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, October 1st will be given a dividend of $0.17 per share. The ex-dividend date is Tuesday, October 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.74%. This is a boost from Encompass Health’s previous quarterly dividend of $0.15. Encompass Health’s payout ratio is 16.22%.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.